ロード中...
Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer
One of the main hallmarks of cancer is the capability of evading immune destruction. In order to drive tumor progression, malignant cells are able to promote immunosuppressive mechanisms avoiding recognition and elimination. Increasing knowledge of the mechanisms of immune tolerance has led to the i...
保存先:
| 出版年: | Transl Lung Cancer Res |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AME Publishing Company
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4700219/ https://ncbi.nlm.nih.gov/pubmed/26798585 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2015.12.06 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|